A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III cli
about
The OptiMARK clinical development program: summary of safety data.Lower-extremity wounds. 1: Vascular disease assessment.Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance.Safety assessment of gadoversetamide (OptiMARK) administered by power injector.Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.
P2860
A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III cli
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
A multicenter, randomized, dou ...... gy: results of a Phase III cli
@en
type
label
A multicenter, randomized, dou ...... gy: results of a Phase III cli
@en
prefLabel
A multicenter, randomized, dou ...... gy: results of a Phase III cli
@en
P2093
P2860
P1476
A multicenter, randomized, dou ...... gy: results of a Phase III cli
@en
P2093
P2860
P304
P356
10.1002/(SICI)1522-2586(199902)9:2<240::AID-JMRI14>3.0.CO;2-#
P577
1999-02-01T00:00:00Z